Is autoimmune diabetes caused by aberrant immune activity or defective suppression of physiological self-reactivity?

Autoimmunity Reviews

Volumn 12, Issue 5, 2013, Pages 633-637

  Askenasy, Enosh M ^a   Askenasy, Nadir ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Activation induced cell death; Diabetogenic cells; Immune surveillance; Inflammatory insulitis; Physiological autoimmunity; Regulatory T cells; Type 1 diabetes

Indexed keywords

AUTOANTIBODY;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BODY WEIGHT; CLONING; DIABETES MELLITUS; EFFECTOR CELL; HOMEOSTASIS; HUMAN; HYPOTHESIS; IMMUNITY; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; NEGATIVE FEEDBACK; NONHUMAN; NUTRITION; PANCREAS ISLET BETA CELL; PHYSIOLOGY; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIVITY ANALYSIS; UMBILICAL CORD BLOOD;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; HUMANS; ISLETS OF LANGERHANS; SELF TOLERANCE;

EID: 84875248649     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.12.004     Document Type: Review

References (47)

1. Awdeh Z.L., Yunis E.J., Audeh M.J., Fici D., Pugliese A., Larsen C.E., et al. A genetic explanation for the rising incidence of type 1 diabetes, a polygenic disease. J Autoimmun 2006, 27:174-181.
2. Knip M., Siljander H. Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 2008, 7:550-557.
3. Borchers A.T., Uibo R., Gershwin M.E. The geoepidemiology of type 1 diabetes. Autoimmun Rev 2010, 9:355-365.
4. Bach J.F. Infections and autoimmune diseases. J Autoimmun 2005, 25:74-80. [Suppl.].
5. Jerne N.K. The natural-selection theory of antibody formation. Proc Natl Acad Sci U S A 1955, 4i:849-856.
6. Bretscher P., Cohn M. A theory of self-nonself discrimination. Science 1970, 169:1042-1049.
7. Burnet F.M. A modification of Jerne's theory of antibody production using the concept of clonal selection. CA Cancer J Clin 1976, 26:119-121.
8. Cohen I.R., Young D.B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol Today 1991, 12:105-110.
9. Poletaev A.B., Stepanyuk V.L., Gershwin M.E. Integrating immunity: the immunculus and self-reactivity. J Autoimmun 2008, 30:68-73.
10. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995, 155:1151-1164.
11. Stanley H.M., Norris J.M., Barriga K., Hoffman M., Yu L., Miao D., et al. Diabetes Autoimmunity Study in the Young (DAISY). Is presence of islet autoantibodies at birth associated with development of persistent islet autoimmunity?. Diabetes Care 2004, 27:497-502.
12. Merbl Y., Zucker-Toledano M., Quintana F.J., Cohen I.R. Newborn humans manifest autoantibodies to defined self molecules detected by antigen microarray informatics. J Clin Invest 2007, 117:712-718.
13. Elfving M., Lindberg B., Lynch K., Månsson M., Sundkvist G., Lernmark A., et al. Number of islet autoantibodies present in newly diagnosed type 1 diabetes children born to non-diabetic mothers is affected by islet autoantibodies present at birth. Pediatr Diabetes 2008, 9:127-134.
14. Quintana F.J., Hagedorn P.H., Elizur G., Merbl Y., Domany E., Cohen I.R. Functional immunomics: microarray analysis of IgG autoantibody repertoires predicts the future response of mice to induced diabetes. Proc Natl Acad Sci U S A 2004, 101(Suppl. 2):14615-14621.
15. Yarkoni S., Kaminitz A., Sagiv Y., Askenasy N. Targeting of IL-2 receptor with a caspase fusion protein disrupts autoimmunity in prediabetic and diabetic NOD mice. Diabetologia 2010, 53:356-368.
16. Askenasy E.M., Askenasy N., Askenasy J.J. Does lymphopenia preclude restoration of immune homeostasis? The particular case of type 1 diabetes. Autoimmun Rev 2010, 9:687-690.
17. Pearl-Yafe M., Iskovich S., Kaminitz A., Stein J., Yaniv I., Askenasy N. Does physiological beta cell turnover initiate autoimmune diabetes in the regional lymph nodes?. Autoimmun Rev 2006, 5:338-343.
18. Gagnerault M.C., Luan J.J., Lotton C., Lepault F. Pancreatic lymph nodes are required for priming of β cell reactive T cells in NOD mice. J Exp Med 2002, 196:369-377.
19. Sánchez-Castañón M., de las Heras-Castaño G., López-Hoyos M. Autoimmune pancreatitis: an underdiagnosed autoimmune disease with clinical, imaging and serological features. Autoimmun Rev 2010, 9:237-240.
20. Takahashi H., Yamamoto M., Suzuki C., Naishiro Y., Shinomura Y., Imai K. The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity. Autoimmun Rev 2010, 9:591-594.
21. Pearl-Yafe M., Kaminitz A., Yolcu E.S., Yaniv I., Stein J., Askenasy N. Pancreatic islets under attack: cellular and molecular effectors. Curr Pharm Des 2007, 13:749-760.
22. Anderson M.S. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005, 23:447-485.
23. Kaminitz A., Stein J., Yaniv I., Askenasy N. The vicious cycle of apoptotic beta-cell death in type 1 diabetes. Immunol Cell Biol 2007, 85:582-589.
24. von Herrath M., Sanda S., Herold K. Type 1 diabetes as a relapsing-remitting disease?. Nat Rev Immunol 2007, 7:988-994.
25. Serreze D.V., Johnson E.A., Chapman H.D., Graser R.T., Marron M.P., DiLorenzo T.P., et al. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 2001, 50:1992-2000.
26. You S., Belghith M., Cobbold S., Alyanakian M.A., Gouarin C., Barriot S., et al. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 2005, 54:1415-1422.
27. D'Alise A.M., Auyeung V., Feuerer M., Nishio J., Fontenot J., Benoist C., et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci U S A 2008, 105:19857-19862.
28. Decallonne B., van Etten E., Giulietti A., Casteels K., Overbergh L., Bouillon R., et al. Defect in activation induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003, 20:219-226.
29. Kishimoto H., Sprent J. A defect in central tolerance in NOD mice. Nat Immunol 2001, 2:1025-1031.
30. Kaminitz A., Yolcu E.S., Askenasy E.M., Stein J., Yaniv I., Shirwan H., et al. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLoS One 2011, 6:e21630.
31. Gregori S., Giarratana N., Smiroldo S., Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003, 171:4040-4047.
32. Askenasy N., Kaminitz A., Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008, 7:370-375.
33. Berzins S.P., Venanzi E.S., Benoist C., Mathis D. T-cell compartments of prediabetic NOD mice. Diabetes 2003, 52:327-334.
34. Putnam A.L., Vendrame F., Dotta F., Gottlieb P.A. CD4+CD25high regulatory T cells in human autoimmune diabetes. J Autoimmun 2005, 24:55-62.
35. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
36. Herbelin A., Gombert J.M., Lepault F., Bach J.F., Chatenoud L. Mature mainstream TCR alpha beta(+)CD4(+) thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse. J Immunol 1998, 161:2620-2628.
37. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
38. Jaeckel E., von Boehmer H., Manns M.P. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005, 54:306-310.
39. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004, 199:1455-1465.
40. Yarkoni S., Kaminitz A., Sagiv Y., Yaniv I., Askenasy N. Involvement of IL-2 in homeostasis of regulatory T cells: the IL-2 cycle. Bioessays 2008, 30:875-888.
41. Banz A., Pontoux C., Papiernik M. Modulation of Fas-dependent apoptosis: a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells. J Immunol 2002, 169:750-757.
42. Taams L.S., Smith J., Rustin M.H., Salmon M., Poulter L.W., Akbar A.N. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 2001, 31:1122-1131.
43. Fritzsching B., Oberle N., Eberhardt N., Quick S., Haas J., Wildemann B., et al. In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 2005, 175:32-36.
44. Yolcu E.S., Ash S., Kaminitz A., Sagiv Y., Askenasy N., Yarkoni S. Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol 2008, 86:650-658.
45. Klein L., Khazaie K., von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 2003, 100:8886-8891.
46. Kaminitz A., Askenasy E.M., Yaniv I., Stein J., Askenasy N. Apoptosis of purified CD4+ T cell subsets is dominated by cytokine deprivation and absence of other cells in new onset diabetic NOD mice. PLoS One 31 2010, 5:e15684.
47. Lan R.Y., Selmi C., Gershwin M.E. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 2008, 31:7-12.